S&P 500   3,977.53 (+0.16%)
DOW   32,432.08 (+0.60%)
QQQ   308.76 (-0.69%)
AAPL   158.28 (-1.23%)
MSFT   276.38 (-1.49%)
META   202.84 (-1.54%)
GOOGL   102.46 (-2.83%)
AMZN   98.04 (-0.09%)
TSLA   191.81 (+0.74%)
NVDA   265.31 (-0.93%)
NIO   8.93 (-1.54%)
BABA   86.12 (-0.90%)
AMD   96.61 (-1.37%)
T   18.87 (+1.40%)
F   11.52 (+0.09%)
MU   59.79 (-2.24%)
CGC   1.88 (-1.05%)
GE   93.31 (+2.12%)
DIS   95.62 (+1.64%)
AMC   4.55 (+1.79%)
PFE   40.22 (-0.42%)
PYPL   73.30 (-0.79%)
NFLX   327.66 (-0.22%)
S&P 500   3,977.53 (+0.16%)
DOW   32,432.08 (+0.60%)
QQQ   308.76 (-0.69%)
AAPL   158.28 (-1.23%)
MSFT   276.38 (-1.49%)
META   202.84 (-1.54%)
GOOGL   102.46 (-2.83%)
AMZN   98.04 (-0.09%)
TSLA   191.81 (+0.74%)
NVDA   265.31 (-0.93%)
NIO   8.93 (-1.54%)
BABA   86.12 (-0.90%)
AMD   96.61 (-1.37%)
T   18.87 (+1.40%)
F   11.52 (+0.09%)
MU   59.79 (-2.24%)
CGC   1.88 (-1.05%)
GE   93.31 (+2.12%)
DIS   95.62 (+1.64%)
AMC   4.55 (+1.79%)
PFE   40.22 (-0.42%)
PYPL   73.30 (-0.79%)
NFLX   327.66 (-0.22%)
S&P 500   3,977.53 (+0.16%)
DOW   32,432.08 (+0.60%)
QQQ   308.76 (-0.69%)
AAPL   158.28 (-1.23%)
MSFT   276.38 (-1.49%)
META   202.84 (-1.54%)
GOOGL   102.46 (-2.83%)
AMZN   98.04 (-0.09%)
TSLA   191.81 (+0.74%)
NVDA   265.31 (-0.93%)
NIO   8.93 (-1.54%)
BABA   86.12 (-0.90%)
AMD   96.61 (-1.37%)
T   18.87 (+1.40%)
F   11.52 (+0.09%)
MU   59.79 (-2.24%)
CGC   1.88 (-1.05%)
GE   93.31 (+2.12%)
DIS   95.62 (+1.64%)
AMC   4.55 (+1.79%)
PFE   40.22 (-0.42%)
PYPL   73.30 (-0.79%)
NFLX   327.66 (-0.22%)
S&P 500   3,977.53 (+0.16%)
DOW   32,432.08 (+0.60%)
QQQ   308.76 (-0.69%)
AAPL   158.28 (-1.23%)
MSFT   276.38 (-1.49%)
META   202.84 (-1.54%)
GOOGL   102.46 (-2.83%)
AMZN   98.04 (-0.09%)
TSLA   191.81 (+0.74%)
NVDA   265.31 (-0.93%)
NIO   8.93 (-1.54%)
BABA   86.12 (-0.90%)
AMD   96.61 (-1.37%)
T   18.87 (+1.40%)
F   11.52 (+0.09%)
MU   59.79 (-2.24%)
CGC   1.88 (-1.05%)
GE   93.31 (+2.12%)
DIS   95.62 (+1.64%)
AMC   4.55 (+1.79%)
PFE   40.22 (-0.42%)
PYPL   73.30 (-0.79%)
NFLX   327.66 (-0.22%)
NASDAQ:IMV

IMV - IMV Stock Forecast, Price & News

$0.51
-0.03 (-5.56%)
(As of 03/27/2023 12:00 AM ET)
Add
Compare
Today's Range
$0.48
$0.58
50-Day Range
$0.51
$3.02
52-Week Range
$0.48
$15.00
Volume
99,082 shs
Average Volume
247,372 shs
Market Capitalization
$5.97 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

IMV MarketRank™ Forecast

Analyst Rating
N/A
Upside/​Downside
N/A
Short Interest
Healthy
0.78% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.47mentions of IMV in the last 14 days
Based on 5 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($4.71) to ($3.10) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.12 out of 5 stars


IMV stock logo

About IMV (NASDAQ:IMV) Stock

IMV, Inc. is a clinical-stage biopharmaceutical company, which engaged in providing a novel class of cancer immunotherapies and vaccines against infectious diseases including COVID-19. The firm leverages its delivery platform (DPX) that programs immune cells directly within the human body to produce robust and sustained target killing capabilities. Its drug candidate, DPX-Survivac is a targeted T cell therapy that has completed multiple phases 1 and 1b trials generating results in late-stage ovarian cancer and relapsed/refractory DLBCL (Diffuse Large B Cell Lymphoma) where it has identified a predictive biomarker. The company was founded on May 18, 2007 and is headquartered in Dartmouth, Canada.

Receive IMV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for IMV and its competitors with MarketBeat's FREE daily newsletter.

IMV Stock News Headlines

IMV Inc. (NASDAQ:IMV) Q4 2022 Earnings Call Transcript
Biden To Unleash "Choke Point" Operation On America?
Biden's disturbing new government program may be worse than Obama's. You are at risk for having your bank account frozen. A former bank regulator is blowing the whistle on Biden's frightening plan to take over your money. Discover the immediate steps you need to take now.
IMV Inc. PT Lowered to $19 at H.C. Wainwright
Biden To Unleash "Choke Point" Operation On America?
Biden's disturbing new government program may be worse than Obama's. You are at risk for having your bank account frozen. A former bank regulator is blowing the whistle on Biden's frightening plan to take over your money. Discover the immediate steps you need to take now.
IMV Shareholders Approve Reverse Stock Split at 88%
Go Ahead, Joke About the Pandemic
See More Headlines
Receive IMV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for IMV and its competitors with MarketBeat's FREE daily newsletter.

IMV Company Calendar

Last Earnings
3/16/2023
Today
3/27/2023
Next Earnings (Estimated)
5/12/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:IMV
Fax
N/A
Employees
97
Year Founded
N/A

Profitability

Net Income
$-37,990,000.00
Net Margins
-11,547.42%
Pretax Margin
-11,547.42%
Return on Equity
-12,695.41%

Debt

Sales & Book Value

Annual Sales
$330,000.00
Book Value
($0.69) per share

Miscellaneous

Free Float
11,673,000
Market Cap
$6.34 million
Optionable
Optionable
Beta
1.00

Key Executives

  • Andrew Hall
    Chief Executive Office & Director
  • Brittany Davison
    Secretary, Chief Financial & Accounting Officer
  • Jeremy R. Graff
    Chief Scientific Officer
  • Stéphane Fiset
    Vice President-Clinical Research
  • Annie Tanguay
    Senior Vice President-Quality & Compliance













IMV Stock - Frequently Asked Questions

Should I buy or sell IMV stock right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for IMV in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" IMV shares.
View IMV analyst ratings
or view top-rated stocks.

How have IMV shares performed in 2023?

IMV's stock was trading at $2.43 at the start of the year. Since then, IMV stock has decreased by 77.7% and is now trading at $0.5418.
View the best growth stocks for 2023 here
.

When is IMV's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, May 12th 2023.
View our IMV earnings forecast
.

How were IMV's earnings last quarter?

IMV Inc. (NASDAQ:IMV) announced its quarterly earnings results on Thursday, March, 16th. The company reported ($0.99) EPS for the quarter, missing analysts' consensus estimates of ($0.92) by $0.07. The firm earned $0.15 million during the quarter. IMV had a negative trailing twelve-month return on equity of 12,695.41% and a negative net margin of 11,547.42%.

When did IMV's stock split?

IMV shares reverse split on Tuesday, December 13th 2022. The 1-10 reverse split was announced on Tuesday, December 13th 2022. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, December 13th 2022. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

What is IMV's stock symbol?

IMV trades on the NASDAQ under the ticker symbol "IMV."

Who are IMV's major shareholders?

IMV's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Armistice Capital LLC (9.15%), Ruffer LLP (4.62%), Jane Street Group LLC (0.92%), Wells Fargo & Company MN (0.49%), First City Capital Management Inc. (0.41%) and LexAurum Advisors LLC (0.34%).

How do I buy shares of IMV?

Shares of IMV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is IMV's stock price today?

One share of IMV stock can currently be purchased for approximately $0.54.

How much money does IMV make?

IMV (NASDAQ:IMV) has a market capitalization of $6.34 million and generates $330,000.00 in revenue each year. The company earns $-37,990,000.00 in net income (profit) each year or ($4.59) on an earnings per share basis.

How can I contact IMV?

IMV's mailing address is 130 EILEEN STUBBS AVENUE SUITE 19, DARTMOUTH A5, B3B 2C4. The official website for the company is imv-inc.com. The company can be reached via phone at (902) 492-1819 or via email at info@imv-inc.com.

This page (NASDAQ:IMV) was last updated on 3/27/2023 by MarketBeat.com Staff